Keywords
Lactation Disorders
Galactagogues
hypogalactia
Domperidone
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: The scope of this work was to carry out an updated review regarding the efficacy, risks and beneits of using Domperidone as a lactation inducer on puerperal women. Bibliographic review: Breastfeeding involves not only biological impulses, but also social, psychological and cultural aspects, being also historically associated with a variety of beliefs and myths. Therefore, the use of unregulated and unapproved lactogenic drugs has increased consideraby as way to mitigate the growing rates of eraly weaning, since an adequate breastfeeding has been scientifically demonstrated to provide benefits for mother and baby. Domperidone is a widely used drug capable of increasing prolactin secretion by the adenohypophysis, as well as antagonizing dopamine effects on milk production. Despite the controversial use of Domperidone as a galactogogue, the adverse effects reports have been limmited to nausea, headaches and dry mouth. However its efficacy, administration length and dosage have not been standardized, being largely variable. Final considerations: Scientifical eveidences have demonstrated that Domperidone is considered safe and moderatly effective in increasing milk production on healty puerperal women after preterm births. However, standardized randomized robust trials are needed to cover a larger amplitude of different at term maternal conditions.
References
ARANA A, et al. Risk of Out-of-Hospital Sudden Cardiac Death in Users of Domperidone, Proton Pump Inhibitors, or Metoclopramide: A Population-Based Nested Case-Control Study. Drug Saf. 2015; 38: 1187–1199.
ASZTALOS EV, et al. Evaluating the Effect of a 14-Day Course of Domperidone on Breast Milk Production: A Per-Protocol Analysis from the EMPOWER Trial. Breastfeeding Medicine, 2018.
AXELSSON PB, et al. Treatment of insufficient lactation is often not evidence-based. Dan Med J., 2014; 61/7.
BAKKER LA, et al. Exploring the Prescribin Process of Domperidone for Low Milk Supply: A Qualitative Study Among Mothers, IBCLCs, and Family Doctors. Journal of human lactation, 2021; 37(4): 748-760.
BRASIL. Manual do Ministério da Saúde. 2014. Disponível em: https://www.gov.br/saude/pt-br/assuntos/saude-de-a-a-z/s/saude-da-crianca/publicacoes/amamentacao-e-uso-de-medicamentos-e-outras-substancias-2a-edicao/view. Acessado em: 15 de setembro de 2022.
FAZILLA TE, et al. Domperidone and maternal milk volume in mothers of premature newborns. Paediatrica Indonesiana, 2017; 57(1): 18–22.
FOONG SC, et al. Oral galactagogues (natural therapies or drugs) for increasing breast milk production in mothers of non-hospitalised term infants. Cochrane Database of Systematic Reviews, 2020; 5(5).
GRZESKOWIAK LE, et al. Factors Associated with Domperidone Use as a Galactogogue at an Australian Tertiary Teaching Hospital. Journal of Human Lactation, 2015; 31(2): 249-53.
GRZESKOWIAK LE, et al. What evidence do we have for pharmaceutical Galactogogues in the treatment of lactation insufficiency? A Narrative Review. Nutrients, 2019; 11(5): 974.
HISHINUMA K, et al. Pregnancy outcome after first trimester exposure to domperidone-An observational cohort study. J Obstet Gynaecol Res. 2021; 47(5): 1704-1710.
IBGE. Instituto Brasileiro de Geografia e Estatística. Crianças com idade igual ou maior que nove menos e menor que 12 meses que estão em aleitamento materno, por situação do domicílio. Brasil, 2013. Disponível em: https://sidra.ibge.gov.br/Tabela/5910#resultado.
IBGE. Instituto Brasileiro de Geografia e Estatística. Crianças com menos de 6 meses de idade que são amamentadas exclusivamente com leite materno, por situação do domicílio. Brasil, 2019. Disponível em: https://sidra.ibge.gov.br/tabela/5905#resultado
INGRAM TJ, et al. Metoclopramide or domperidone for increasing maternal breast milk output: a randomised controlled. Arch Dis Child Fetal Neonatal Ed. 2012; 97: 241–F245.
JANTARASAENGARAM S e SREEWAPA P. Effects of domperidone on augmentation of lactation following cesarean delivery at full term, 2012; 16(3): 240-243.
KARAPATI E, et al. Mothers in Need of Lactation Support May Benefit from Early Postnatal Galactagogue Administration: Experience from a Single Center. Nutrients, 2021; 14(1): 140p.
KHORANA M, et al. Effect of domperidone on breast milk production in mothers of sick neonates: A randomized, double-blinded, placebo-controlled trial. Breastfeed Med., 2021; 16: 245–50.
MCGUIRE TM. Drugs affecting milk supply during lactation. [Internet]. Australian Prescriber. 2018: 41(1): 7–9 p.
MCBRIDE GM, et al. Use and experiences of galactagogues while breastfeeding among Australian women. PLoS ONE, 2021; 16(7).
MORIELLO C, et al. Off-label postpartum use of domperidone in Canada: a multidatabase cohort study. CMAJ OPEN, 2021; 9(2).
OU LB, et al. Domperidone and the risks of sudden cardiac death and ventricular arrhythmia: A systematic review and meta-analysis of observational studies. Brit Jnl Clinical Pharma, 2021; 87: 3649-3658.
RAI R, et al. Effect of domperidone in 2nd week postpartum on milk output in mothers of preterm infants. Indian Journal of Pediatrics. 2016; 83(8): 894–895.
REISMAN T. Goldstein, Z. Case Report: Induced Lactation in a Transgender Woman. Transgender Health, 2018; 3: 1.
SEWELL CA, et al. Domperidone for lactation: what health care providers need to know. Obstet Gynecol. 2017; 129: 1054-8.
SMOLINA K, et al. Postpartum domperidone use in British Columbia: a retrospective cohort study. CMAJ Open, 2016; 4(1).
VICTORA CG, et al. Breastfeeding Series Group. Breastfeeding in the 21st century: epidemiology, mechanisms, and lifelong effect. The Lancet, 2016; 387(10017): 475-490.
ZIZZO R, et al. The risk-risk trade-offs: Understanding factors that influence women’s decision to use substances to boost breast milk supply. PLoS ONE, 2021; 16(5).
ZIZZO R, et al. Fear of stopping” vs “wanting to get off the medication”: exploring women’s experiences of using domperidone as a galactagogue - a qualitative study. International Breastfeeding Journal, 2021; 16(92).
ZUPPA AA, et al. Safety and Efficacy of Galactogogues: Substances that Induce, Maintain and Increase Breast Milk Production. J Pharm Pharmaceut Sci., 2010; 13(2): 162 – 174.